Press Releases

BRISBANE, Calif. , Aug. 15, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag ,

AlloSure launch momentum drives 48% revenue growth BRISBANE, Calif. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for

BRISBANE, Calif. , July 16, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release

Amy Abernethy adds clinical expertise and patient data insights to the CareDx Board BRISBANE, Calif. , June 28, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value

BRISBANE, Calif. , June 19, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announced today that it is set to join

The progressive CareDx Living Donor Employee Recovery Policy announced at ATC BRISBANE, Calif. , June 05, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value

CareDx will have a strong presence at ATC, all major US transplant centers will be in attendance BRISBANE, Calif. , June 01, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated,

BRISBANE, Calif. , May 24, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, will hold a press conference* at 4:00

AlloSure launch momentum drives 21% revenue growth Further expands product offerings for transplant patients BRISBANE, Calif. , May 10, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically

License and Commercialization Agreement with Illumina BRISBANE, Calif. , May 09, 2018 (GLOBE NEWSWIRE) -- CareDx (NASDAQ:CDNA), today announced that, as reported in its Current Report on Form 8-K filed with the Securities Exchange Commission on May 8, 2018 , it entered into a License and